Order Article Reprints

Du J-S, Kuo Y-C, Shi H-Y, Wang M-C, Wang L-Y, Chuang T-M, Ke Y-L, Yeh T-J, Gau Y-C, Wang H-C, et al. The Cost-Effectiveness Analysis of Transplant-Ineligible Myeloma Patients with Bortezomib plus Thalidomide plus Dexamethasone (VTD) or Bortezomib plus Melphalan plus Prednisolone (VMP) Treatment in Southern Taiwan. Journal of Personalized Medicine. 2022; 12(2):130. https://doi.org/10.3390/jpm12020130

Du, Jeng-Shiun, Yi-Chun Kuo, Hon-Yi Shi, Ming-Chung Wang, Li-Ying Wang, Tzer-Ming Chuang, Ya-Lun Ke, Tsung-Jang Yeh, Yu-Ching Gau, Hui-Ching Wang, and et al. 2022. "The Cost-Effectiveness Analysis of Transplant-Ineligible Myeloma Patients with Bortezomib plus Thalidomide plus Dexamethasone (VTD) or Bortezomib plus Melphalan plus Prednisolone (VMP) Treatment in Southern Taiwan" Journal of Personalized Medicine 12, no. 2: 130. https://doi.org/10.3390/jpm12020130

Du, J.-S., Kuo, Y.-C., Shi, H.-Y., Wang, M.-C., Wang, L.-Y., Chuang, T.-M., Ke, Y.-L., Yeh, T.-J., Gau, Y.-C., Wang, H.-C., Cho, S.-F., Hsiao, S. Y., Liu, Y.-C., Hsu, C.-M., & Hsiao, H.-H. (2022). The Cost-Effectiveness Analysis of Transplant-Ineligible Myeloma Patients with Bortezomib plus Thalidomide plus Dexamethasone (VTD) or Bortezomib plus Melphalan plus Prednisolone (VMP) Treatment in Southern Taiwan. Journal of Personalized Medicine, 12(2), 130. https://doi.org/10.3390/jpm12020130